

Repurposing of Modified Giresaflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole to Cure ACE (Angiotensin 1 Converting Enzyme) Gene Mutations in Hypertensive Heart Disease

Ishtiaq Ali^{1*}, Sajid Khan¹, Faisal Nouroz¹, Asma Ibrahim¹, Farzana Bibi¹, Muhammad Hamza², Sajid Khan², Azhar Mehmood², Sara Khan¹ and Rashid Rasheed³

¹Department of Bioinformatics, Hazara University, Mansehra, Pakistan

²Department of Bioinformatics, GPGC Mandian, Abbottabad, Pakistan

³Institute of Nuclear Medicine Oncology and Radiotherapy (INOR), Pakistan.

Received May 20, 2019; Accepted May 21, 2019; Published September 10, 2019

ABSTRACT

Hypertension is the main source of heart disappointment and cardiovascular comorbidities in created nations. Left ventricular auxiliary/practical adjustments, for example, concentric renovating or hypertrophy have been broadly considered in hypertensive heart ailments. Besides, it is likewise all around perceived that diastolic capacity really break down in hypertensive subjects preceding plain heart failure. In this research work FDA rejected Giresaflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole were selected. Drugs were changed on the basis of side effects; modified drugs were docked with ACE (angiotensin 1 changing over chemical) proteins and QSAR analysis was performed. The fewer side effects and docking results of both modified Giresaflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole suggest that both the drugs can be used to cure mutations of genes in hypertensive heart disease as all modified drugs have fewer side-effects and toxicity, as compared to original drugs, all drugs have demonstrated greater interactions with the amino acid residues lying in the pockets of mutated proteins that demonstrates their stability and soundness.

Keywords: QSAR, Giresaflibanserin, Ilariscanakinumab, Remoxyoxycodone, Remoxyoxycodone, Zefteraceftobiprole, FDA, ACE

INTRODUCTION

Both the natural and versatile insusceptible frameworks assume an imperative job in the advancement and movement of heart disappointment (HF). The relationship among HF and aggravation was first perceived in 1990 [1] who detailed hoisted levels of TNF in patients with HF with a lessened discharge division (EF). An ongoing report built up of those patients with hypertensive heart ailments showed more elevated amounts of IL-18, a marker of inflammasome actuation [2]. Hypertensive coronary illness was analyzed within the sight of any or blend of the accompanying variations from the norm: left ventricular diastolic brokenness (e.g. adjusted E:A proportion), left ventricular hypertrophy (ordered LV mass >51 g/m²), left ventricular systolic brokenness and expanded left chamber, a surrogate of disabled LV fling (left atrial distance across >3.8 cm in ladies and >4.2 cm in men) within the sight of hypertension. Left ventricular geometric examples were shield as indicated by Ganau et al. [3]. Changes happening in hypertensive

coronary illness (HHD) and the job of non-intrusive heart imaging arterial hypertension are the commonest reason for cardiovascular passing. It might prompt hypertensive coronary illness (HHD) including heart disappointment (HF), ischemic coronary illness (IHD) and left ventricular hypertrophy (LVH). There is no agreement among new HTN rehearse rules as to target treatment of circulatory strain (BP) among different subpopulations of patients. In any case, most rules currently focus on a BP<150/90 for patients >80

Corresponding author: Ishtiaq Ali, Department of Bioinformatics, Hazara University, Mansehra, Pakistan, E-mail: ishtiaqsawal@gmail.com

Citation: Ali I, Khan S, Nouroz F, Ibrahim A, Bibi F, et al. (2019) Repurposing of Modified Giresaflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole to Cure ACE (Angiotensin 1 Converting Enzyme) Gene Mutations in Hypertensive Heart Disease. J Pharm Drug Res, 2(5): 187-194.

Copyright: ©2019 Ali I, Khan S, Nouroz F, Ibrahim A, Bibi F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

years, a BP<140/90 for patients with diabetes or CVD and a BP<130/80 if diabetes, albuminuria, or high stroke chance is available. In United States, 1 out of each 3 grown-ups has high BP. Around 69% of individuals with first heart assault, 77% with first stroke and 74% with HF have BP higher than 140/90 mm Hg [4]. Fundamental hypertension represents 90% of grown-up cases and auxiliary reasons for hypertension for the staying 10%. As indicated by the Framingham Study, hypertension represents around 1/4 of HF cases and the danger of HF is expanded by 2-overlap in men and 3-crease in ladies, separately. At long last, hypertension influences other target organs including kidneys, eyes and fringe conduits [5]. Hypertension is a standout amongst the most normally experienced patient issues in day by day clinical practice. As a main source of unfriendly cardiovascular occasions in created social orders, the hidden systems, pathophysiology and clinical outcomes of hypertension are progressively winding up more broadly recognized [6]. Hypertension is the main source of heart disappointment and cardiovascular comorbidities in created nations. Left ventricular auxiliary/practical adjustments, for example, concentric renovating or hypertrophy have been broadly considered in hypertensive heart ailments. Besides, it is likewise all around perceived that diastolic capacity really break down in hypertensive subjects preceding plain heart failure [7]. Hypertension is an exceptionally pervasive ailment related with cardiovascular dreariness and mortality. Ongoing investigations recommend that patients with hypertension likewise have an insufficiency of certain heart peptides. Already we exhibited that a solitary intravenous infusion of the myocardium-tropic adeno-related infection (AAV) 9-based vector encoding for proBNP kept the advancement of hypertensive coronary illness (HHD) in unexpectedly hypertensive rats (SHRs). The present investigation was intended to decide the length of cardiovascular transduction after a solitary AAV9 infusion and to decide if heart BNP overexpression can postpone the movement of beforehand settled HHD and enhance survival in matured SHRs with plain HHD [8]. Hypertension (HTN) is a noteworthy supporter of the worldwide weight of cardiovascular ailment, prompting stroke, myocardial dead tissue, heart disappointment (HF) and passing [9]. Numerous coronary illness and stroke passing could be maintained a strategic distance from through enhancements in way of life practices, treatment of hazard factors and tending to the social determinants of wellbeing (i.e., financial and social conditions that impact the strength of people and networks). Unfortunate way of life practices (e.g. tobacco utilize, lacking physical action, terrible eating routine and over the top liquor utilize) combined with uncontrolled hypertension, hoisted cholesterol, and stoutness represent 80% of ischemic coronary illness mortality and around half of stroke mortality in high-wage nations, for example, the United States [10]. The heart regularly reacts with hypertrophic development, portrayed by expanding myocytes measure and cardiovascular divider thickness, in different pathologic

conditions, for example, hypertension, myocardial localized necrosis, perpetual ischemia and valvular sickness [11]. Hypertensive coronary illness is the objective organ reaction to blood vessel hypertension. Left ventricular hypertrophy speaks to an essential indicator for cardiovascular occasions. Myocardial fibrosis, a typical end point in hypertensive coronary illness, has been connected to the advancement of left ventricular hypertrophy and diastolic brokenness. Echocardiography is clinically valuable in the recognition of left ventricular hypertrophy and the appraisal of diastolic capacity. In spite of the fact that echocardiography is all the more broadly accessible, cardiovascular attractive reverberation has been shown to be more reproducible for the estimation of left ventricular mass [12]. Hypertensive coronary illness (HHD) is the objective organ reaction to foundational blood vessel hypertension. Patients with longstanding hypertension are at expanded hazard for growing left ventricular hypertrophy (LVH) and diastolic brokenness [13]. The distinguishing proof of LVH in the hypertensive patient is critical from a prognostic angle. It recognizes the patient with hypertension who may require more forceful BP control. In patients with basic hypertension and standard LVH on ECG, bring down LVM amid antihypertensive treatment is related with lower rates of clinical end focuses, freely of the impacts of BP bringing down and treatment methodology [14]. Hypertension prompts cardiovascular tissue hypothyroidism, a condition that can without anyone else prompt heart disappointment. We have beforehand demonstrated that transient thyroid hormone treatment in Spontaneously Hypertensive Heart Failure (SHHF) rats close heart disappointment is useful. This investigation tried the theory that remedial, long haul T3 treatment in SHHF rats can avoid or constrict heart brokenness. Female SHHF rats were dealt with orally with a physiological T3 measurement (0.04 µg/ml) from 12 to 24 months of age [15].

MATERIALS AND METHODS

Data about the ACE (angiotensin 1 changing over chemical) related with Hypertensive coronary illness was gotten through writing [16]. Transformed protein ids of ACE (angiotensin 1 changing over chemical) proteins were downloaded through Research collaborator for basic Bioinformatics (RCSB) protein database (PDB). RCSB PDB is for the most part a database that involves X-beam crystallographic and atomic attractive The Protein Data Bank (PDB) is the single overall document of tentatively decided three-dimensional (3D) structures of proteins and nucleic acids it is accessible at <https://www.rcsb.org> [17]. The 3D structures of proteins are shown in **Figure 1**. Compound structure of Girosafliabanserin, Ilariscanakinumab, Remoxyoxycodone and Zeferaceftobiprole were gotten through PubChem database. PubChem is an open database of the compound structures and natural test outcomes, accessible at <http://pubchem.ncbi.nlm.nih.gov> [18]. The substance

structures of Girosafliabanserine, Ilariscanakinumab, PubChem are shown in **Figure 2**. Remoxyoxycodone and Zefteraceftobiprole got through




Figure 1. Mutated protein 3D structure of ACE (angiotensin 1 converting enzyme) gene.




Figure 2. Chemical structures of original Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole downloaded through PubChem database, a) Girosafliabanserine; b) Ilariscanakinumab; c) Remoxyoxycodone; and d) Zefteraceftobiprole.

Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole were checked for their danger esteems by the utilization of Protox server. Protox is a webserver utilized for the forecast of oral poisonous quality estimations of little medication mixes in the rodents. It is accessible at <https://www.tox.charite.de/> [19]. Likelihood of reactions and genotoxicity risks of both the medications were dissected through ACD Labs server, accessible at <https://ilab.acdlabs.com/>. The ACD Labs server is normally utilized for the *in silico* prediction of physicochemical, ADME and toxicity properties of medication applicants. It enables researchers to comprehend QSAR connections and to clarify the conduct of novel medication hopefuls. After the estimation of symptoms proportions, all the Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole were altered to decrease the reactions and new mixes were composed in revelation studio programming with lessened symptoms and poisonous quality. After change, the new compound structures of the

Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole were checked for harmfulness and symptoms from similar servers that were utilized previously, based on better outcomes all the Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole were docked with the downloaded 3D structure of transformed proteins through the fix dock server [20]. Based on results, it is recommended that all the altered Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zefteraceftobiprole can be utilized to treat transformations of hypertensive heart maladies qualities. The likelihood of reactions of altered Girosafliabanserine got through ACD Labs is shown in **Table 1**. **Tables 2-4** exhibited that the adjusted Girosafliabanserine has less symptoms in a few organs of the body when contrasted with unique Girosafliabanserine in this way, it is less poisonous in nature, it will demonstrate better outcomes in the treatment of hypertensive heart sicknesses, being non-lethal in nature.

Table 1. Comparison between the probability ratios of side effects of modified Givosafliabanserine and original Givosafliabanserine.

Probability of side effects of modified Givosafliabanserine		Probability of side effects of original Givosafliabanserine	
Organs	Ratio	Organs	Ratio
Blood	0.51	Blood	0.31
Cardio-vascular system	0.94	Cardio-vascular system	0.96
Kidneys	0.74	Kidneys	0.37
Liver	0.76	Liver	0.16
Lungs	0.86	Lungs	0.84

Table 2. Comparison between the probability ratios of side effects of modified Ilariscanakinumab and original Ilariscanakinumab.

Probability of side effects of modified Ilariscanakinumab		Probability of side effects of original Ilariscanakinumab	
Organs	Ratio	Organs	Ratio
Blood	0.22	Blood	0.12
Cardio-vascular system	0.38	Cardio-vascular system	0.26
Kidneys	0.04	Kidneys	0.09
Liver	0.09	Liver	0.1
Lungs	0.19	Lungs	0.33

Table 3. Comparison between the probability ratios of side effects of modified Remoxyoxycodone and original Remoxyoxycodone.

Probability of side effects of modified I Remoxyoxycodone		Probability of side effects of original Remoxyoxycodone	
Organs	Ratio	Organs	Ratio
Blood	0.85	Blood	0.62
Cardio-vascular system	0.95	Cardio-vascular system	0.33
Kidneys	0.7	Kidneys	0.41
Liver	0.8	Liver	0.31
Lungs	0.88	Lungs	0.83


Table 4. Comparison between the probability ratios of side effects of modified Zeftoracetobiprole and original Zeftoracetobiprole.

Probability of side effects of modified I Zeftoracetobiprole		Probability of side effects of original Zeftoracetobiprole	
Organs	Ratio	Organs	Ratio
Blood	0.97	Blood	0.81
Cardio-vascular system	0.2	Cardio-vascular system	0.18
Kidneys	0.64	Kidneys	0.16
Liver	0.64	Liver	0.37
Lungs	0.1	Lungs	0.03

RESULTS

It was seen that, before alterations in the compound structures of Giraflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zeftoracetobiprole, the harmfulness estimation of Giraflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zeftoracetobiprole, which was not dependable and viewed as perilous. What's more, all the mixes were laying in the high harmful classification of classes, for example, class 2. The probability proportion of

reactions of original Giraflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zeftoracetobiprole were likewise exceptionally high. The adjusted Giraflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zeftoracetobiprole are shown in **Figure 3**. The nearness of a Cl and H iota alongside the fragrant ring was a reason for genotoxicity, in this way; the Cl and H particle was expelled and supplanted with O molecule, which results in the decrease of harmfulness.

**Figure 3.** Modified Giraflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zeftoracetobiprole in which one Cl from the ring is replaced by O and also remove hydrogen atom and oxygen with double bound to make it less toxic.

There are a few classes of danger as indicated by the internationally blended arrangement of grouping of naming of synthetic compounds fewer reactions in a few organs of the body when contrasted with unique Giraflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zeftoracetobiprole along these lines, it is non-dangerous in nature, it will demonstrate better outcomes in the treatment of Hypertensive coronary illness. Typically; medicate disclosure ventures based the examining for lead structures.

In any case; Virtual screening and sub-atomic docking establishes remarkable alternatives to find hit mixes. Novel malady targets can similarly be described and used together with sub-atomic docking devices utilized in medication revelation programs [16]. The docked aftereffects of changed Giraflibanserin, Ilariscanakinumab, Remoxyoxycodone and Zeftoracetobiprole with ACE (angiotensin 1 changing over chemical) protein are appeared in **Figure 4**.




Figure 4. Docked complexes of modified Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zeftaceftobiprole along with ACE (angiotensin 1 converting enzyme) protein and interactions of modified Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zeftaceftobiprole with amino acid residues of ACE (angiotensin 1 converting protein).

The less symptoms and docking consequences of all adjusted Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zeftaceftobiprole recommends that every one of the medications can be utilized to fix transformations of ACE (angiotensin 1 changing over compound) in hypertensive coronary illness as every single altered medication have less reactions and danger esteems. When contrasted with unique medications, all medications showed more noteworthy cooperation with the amino corrosive buildups lying in the pockets of transformed proteins that exhibit their solidness and soundness. The more noteworthy the cooperation, the better are the mixes as a medication applicant. Medication repurposing has a few points of interest and the undertakings have been driven by a couple of basic parts including; the entrance to growing proportions of exploratory data, better perception of compound poly pharmacology and natural data mining. *In silico* procedures, either receptor-based or ligand-based, have been adjusted to sedate repurposing adventures. As of late repurposing approaches are used for huge scale testing of medication activities on reaction targets [21].

DISCUSSION

Hypertensive coronary illness treatment on a very basic level; centers around medication repurposing frameworks for two reasons. As an issue of first significance, repurposing of insisting and surrendered drugs for hypertensive coronary illness speaks to an opportunity to rapidly advance to patients promising medicine medications by profiting from existing data and experience. A similar

system stays steady for surrendered or “resigned” pharmaceuticals, whose improvement was suspended due to non-safety related reasons [22]. In this examination venture, a similar methodology is utilized to repurpose surrendered tranquilizers by making some change in mixes to make the medication compound helpful in the treatment of hypertensive coronary illness. *In silico* procedures, both the receptor-based and ligand-based, have been associated with sedate repurposing adventures. Keiser et al. [23] foreseen and endorsed 23 novel medicine target communications using two-dimensional compound similarity approach. Ligand-based quantitative structure-action relationship models have been used by Yang et al. to predict signs for 145 ailments using the responses as highlighted [24].

CONCLUSION

The likelihood of reactions of adjusted Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zeftaceftobiprole is not as much as unique Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zeftaceftobiprole. In docked buildings and QSAR investigation, the two medications have exhibited more prominent associations with the amino corrosive deposits lying in the pockets of changed proteins that show their strength and soundness. The less symptoms and docking consequences of all altered Girosafliabanserine, Ilariscanakinumab, Remoxyoxycodone and Zeftaceftobiprole recommend that every one of the medications can be utilized to fix changes of qualities in Hypertensive coronary illness as every single adjusted

medication have less reactions and lethality when contrasted with unique medications. In future, this exploration work can be utilized as a piece of clinical preliminaries to check its capability and social significance.

ACKNOWLEDGEMENT

Authors are grateful to Bioinformatics International Research Club Abbottabad for providing a platform to conduct research.

CONFLICT OF INTEREST

This research work is unique and has not been submitted to any other journal. None of the authors have any challenged conflicts of interest.

REFERENCES

1. Africa S (2017) HHS. Public Access 4: 1254-1268.
2. Drazner MH (2011) The progression of hypertensive heart disease. *Circulation* 123: 327-334.
3. Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R (2014) ProTox: A web server for the in silico prediction of rodent oral toxicity. *Nucleic Acids Res* 42: 3-8.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2014) Executive summary: Heart disease and stroke statistics - 2014 update: A report from the American Heart Association. *Circulation* 129: 399-410.
5. Goetze JP, Hilsted LM, Rehfeld JF, Alehagen U (2014) Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure. *Endocrine Connections* 3: 47-56.
6. Guerrero-Perilla C, Bernal FA, Coy-Barrera ED (2015) Molecular docking study of naturally occurring compounds as inhibitors of N-myristoyl transferase towards antifungal agents discovery. *Resumen Acoplamiento molecular de compuestos de origen natural como* 44: 162-178.
7. Janardhanan R, Kramer CM (2011) Imaging in hypertensive heart disease. *Expert Rev Cardiovasc Ther* 9: 199-209.
8. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. *Nature* 462: 175-181.
9. Korkmaz S, Duarte JM, Prlic A, Goksuluk D, Zararsiz G, et al. (2018) Investigation of protein quaternary structure via stoichiometry and symmetry information. *PLoS One* 13: 1-20.
10. Lai Y, Lo C, Wu Y, Hung C, Yeh H (2013) Cardiac remodeling, adaptations and associated myocardial mechanics in hypertensive heart diseases. *Zhonghua Minguo Xin Zang Xue Hui Za Zhi* 29: 64-70.
11. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL (2006) Global and regional burden of disease and risk factors 2001: Systematic analysis of population health data. *Lancet* 367: 1747-1757.
12. Miura K, Dyer AR, Greenland P, Daviglus ML, Hill M, et al. (2001) Pulse pressure compared with other blood pressure indexes in the prediction of 25 year cardiovascular and all-cause mortality rates. *Hypertension* 38: 232-237.
13. Natesh R, Schwager SLU, Evans HR, Sturrock ED, Acharya KR (2004) Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. *Biochemistry* 43: 8718-8724.
14. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, et al. (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA* 292: 2350-2356.
15. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan, et al. (1990) Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *N Engl J Med* 323: 570-578.
16. Sani Isa M, Bala GS, Oyati AI, Danbauchi SS (2010) Patterns of left ventricular hypertrophy and geometry in newly diagnosed hypertensive adults in Northern Nigerians. *J Diabetes Endocrinol* 1: 1-5.
17. Schiros CG, Desai RV, Venkatesh BA, Gaddam KK, Agarwal S, et al. (2014) Left ventricular torsion shear angle volume analysis in patients with hypertension: A global approach for LV diastolic function. *J Cardiovasc Magn Reson* 16: 1-7.
18. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock and SymmDock: Servers for rigid and symmetric docking. *Nucleic Acids Res* 33: 363-367.
19. Tonne JM, Holditch SJ, Oehler EA, Schreiber CA, Ikeda Y, et al. (2014) Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease. *Aging* 6: 311-319.
20. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2009) PubChem: A public information system for analyzing bioactivities of small molecules. *Nucleic Acids Res* 37: 623-633.
21. Weir SJ, DeGennaro LJ, Austin CP (2012) Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. *Cancer Res* 72: 1055-1058.

22. Weltman NY, Pol CJ, Zhang Y, Wang Y, Koder A, et al. (2015) Long-term physiological T3 supplementation in hypertensive heart disease in rats. *Am J Physiol Heart Circ Physiol* 309: 1059-1065.
23. Xu J, Liu Y, Xie Y, Zhao C, Wang H (2017) Bioinformatics analysis reveals microRNAs regulating biological pathways in exercise-induced cardiac physiological hypertrophy. *BioMed Res Int*.
24. Yang L, Agarwal P (2011) Systematic drug repositioning based on clinical side-effects. *PLoS One* 6.